• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

    3/24/23 6:09:00 AM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email
    SC 13G 1 ea175702-13gstfortune_anpac.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. )*

     

    AnPac Bio-Medical Science Co., Ltd.
    (Name of Issuer)
     
    Class A Ordinary Shares
    (Title of Class of Securities)

     

    1411 Broadway FL16 New York NY

    Haohan Xu

    001 646 409 6505

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    03635R206
    (CUSIP Number)

     

    March 24, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 03635R206 13G  

     

    1

    NAME OF REPORTING PERSONS

    ST. FORTUNE GROUP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

    (a) ☐

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH

    5

    SOLE VOTING POWER

    ---

    6

    SHARED VOTING POWER

    14,214,285 Class A Ordinary Shares

    7

    SOLE DISPOSITIVE POWER

    ---

    8

    SHARED DISPOSITIVE POWER

    14,214,285 Class A Ordinary Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,214,285 Class A Ordinary Shares

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    12.81% (1)

    12

    TYPE OF REPORTING PERSON (See instructions)

    OO

     

    1)The calculations in the table above are based on 110,977,640 ordinary shares (including 107,404,540 Class A ordinary shares and 3,573,100 Class B ordinary shares) outstanding as of March 17, 2023.

     

    2

     

     

    CUSIP No. 03635R206 13G  

     

    1

    NAME OF REPORTING PERSONS

    Duo Liu

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)

    (a) ☐

    (b) ☒

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING PERSON WITH

    5

    SOLE VOTING POWER

    ---

    6

    SHARED VOTING POWER

    14,214,285 Class A Ordinary Shares

    7

    SOLE DISPOSITIVE POWER

    ---

    8

    SHARED DISPOSITIVE POWER

    14,214,285 Class A Ordinary Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    14,214,285 Class A Ordinary Shares

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    12.81% (1)

    12

    TYPE OF REPORTING PERSON (See instructions)

    IN

     

    1)The calculations in the table above are based on 110,977,640 ordinary shares (including 107,404,540 Class A ordinary shares and 3,573,100 Class B ordinary shares) outstanding as of March 17, 2023.

     

    3

     

     

    Item 1.

     

    (a)Name of Issuer:

     

    ANPAC BIO-MEDICAL SCIENCE CO., LTD. (the “Issuer”).

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    1411 Broadway FL16 New York NY USA

     

    Item 2.

     

    (a)Name of Person Filing:

     

    (b)Address of Principal Business Office:

     

    (c)Citizenship:

     

    ST. FORTUNE GROUP LLC

    39 Applegreen Drive, Old Westbury, NY 11568

    Citizenship: Delaware

     

    Ms. Duo Liu

    c/o ST. FORTUNE GROUP LLC

    39 Applegreen Drive, Old Westbury, NY 11568

    Citizenship: USA

     

    (d)Title of Class of Securities:

     

    Class A Ordinary Shares

     

    (e)CUSIP Number:

     

    03635R206

     

    Item 3. Not applicable.

     

    4

     

     

    Item 4. Ownership:

     

      (a) Amount beneficially owned:

     

     

    See row 9 of cover page of each reporting person.

     

    The managing member of St. Fortune Group is Ms. Duo Liu (the LLC is owned 50% by Ms. Duo Liu and 50% by Mr. Ruolei Liu, her father.) Therefore, Ms. Liu may also be deemed to have shared voting control and investment discretion over securities owned by St. Fortune Group.

     

      Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group. In addition, each of the Filing Persons disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons that they are the beneficial owners of any of the shares covered by this Statement, and each of Filing Persons disclaims beneficial ownership of any such shares.

     

      (b) Percent of class:

     

      See row 11 of cover page of each reporting person

     

      (c) Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

     

    See row 5 of cover page of each reporting person

     

      (ii)

    Shared power to vote or to direct the vote:

     

    See row 6 of cover page of each reporting person and note in Item 4(a) above

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

    See row 7 of cover page of each reporting person

     

      (iv)

    Shared power to dispose or to direct the disposition of:

     

    See row 8 of cover page of each reporting person and note in Item 4(a) above

     

    5

     

     

    Item 5. Ownership of Five Percent or Less of a Class:

     

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another:

     

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group:

     

    See Exhibit I.

     

    Item 9.

    Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.

    Certification:

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    6

     

     

    CUSIP No. 03635R206

    13G  

     

    Exhibit I  Joint Filing Agreement

     

    7

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: March 24, 2023

     

      ST. FORTUNE GROUP LLC
       
      By: /s/ Duo Liu
      Name:  Duo Liu
      Title: Manager

     

      By: /s/ Duo Liu
        Duo Liu

     

    8

     

     

    EXHIBIT I

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree that only one statement containing the information required by Schedule 13G and any further amendments thereto needs to be filed with respect to the beneficial ownership by each of the undersigned relating to Class A Ordinary Shares of AnPac Bio-Medical Science Co., Ltd, and further agree that this Joint Filing Agreement be included as an exhibit to the Schedule 13G, provided that, as contemplated by Section 13d-1(k)(1)(ii), no person shall be responsible for the completeness or accuracy of the information concerning any other person making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement as to Joint Filing may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

     

    Dated: March 24, 2023

     

      ST. FORTUNE GROUP LLC
       
      By: /s/ Duo Liu
      Name:  Duo Liu
      Title: Manager

     

      Duo Liu
       
      By: /s/ Duo Liu
        Duo Liu

     

     

     

    9

     

    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    SEC Filings

    See more

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care